Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 20, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Report Second Quarter 2023 Financial Results on August 3

RESEARCH TRIANGLE PARK, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results...
July 19, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey

RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals...
July 17, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Participate in the 2023 US HAEA National Summit

RESEARCH TRIANGLE PARK, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced its participation at the 2023 US Hereditary Angioedema Association...
July 06, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 06, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
June 06, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., June 06, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
June 01, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., June 01, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Jefferies Healthcare Conference on...
May 31, 2023 07:02 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress

RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will present two abstracts featuring data on oral,...
May 22, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile

RESEARCH TRIANGLE PARK, N.C., May 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Public Health Institute (ISP) of Chile has granted marketing...
May 04, 2023 16:01 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
May 03, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update

—Q1 2023 ORLADEYO net revenue grows 38 percent y-o-y to $68.4 million— —Strong ORLADEYO new patient growth in Q1: 46 percent increase in patients on therapy y-o-y, including eight percent growth...